Characterization of virulent T4-Like Acinetobacter baumannii bacteriophages DLP1 and DLP2

Par Conseil national de recherches du Canada

Téléchargement	Voir la version finale : Characterization of virulent T4-Like Acinetobacter baumannii bacteriophages DLP1 and DLP2 (PDF, 16.1 Mio)
DOI	Trouver le DOI : https://doi.org/10.3390/v15030739
Auteur	Rechercher : Peters, Danielle L.¹; Rechercher : Davis, Carly M.¹Identifiant ORCID : https://orcid.org/0000-0001-8985-3998; Rechercher : Harris, Greg¹; Rechercher : Zhou, Hongyan¹; Rechercher : Rather, Philip N.; Rechercher : Hrapovic, Sabahudin²; Rechercher : Lam, Edmond²; Rechercher : Dennis, Jonathan J.Identifiant ORCID : https://orcid.org/0000-0002-3925-9533; Rechercher : Chen, Wangxue¹Identifiant ORCID : https://orcid.org/0000-0003-0958-7728
Affiliation	Conseil national de recherches du Canada. Thérapeutique en santé humaine Conseil national de recherches du Canada. Développement des cultures et des ressources aquatiques
Bailleur de fonds	Rechercher : National Research Council (NRC) Canada’s Ideation Small Team Project (National Program Office); Rechercher : Natural Sciences and Engineering Research Council of Canada Discovery grant; Rechercher : United States Department of Veterans Affairs
Format	Texte, Article
Sujet	bacteriophage; Acinetobacter baumannii; phage therapy; lytic phage; antimicrobial resistance; phage; T4-like phage; Acinetobacter phage
Résumé	The world is currently facing a global health crisis due to the rapid increase in antimicrobial-resistant bacterial infections. One of the most concerning pathogens is Acinetobacter baumannii, which is listed as a Priority 1 pathogen by the World Health Organization. This Gram-negative bacterium has many intrinsic antibiotic resistance mechanisms and the ability to quickly acquire new resistance determinants from its environment. A limited number of effective antibiotics against this pathogen complicates the treatment of A. baumannii infections. A potential treatment option that is rapidly gaining interest is “phage therapy”, or the clinical application of bacteriophages to selectively kill bacteria. The myoviruses DLP1 and DLP2 (vB_AbaM-DLP_1 and vB_AbaM-DLP_2, respectively) were isolated from sewage samples using a capsule minus variant of A. baumannii strain AB5075. Host range analysis of these phages against 107 A. baumannii strains shows a limited host range, infecting 15 and 21 for phages DLP1 and DLP2, respectively. Phage DLP1 has a large burst size of 239 PFU/cell, a latency period of 20 min, and virulence index of 0.93. In contrast, DLP2 has a smaller burst size of 24 PFU/cell, a latency period of 20 min, and virulence index of 0.86. Both phages show potential for use as therapeutics to combat A. baumannii infections.
Date de publication	2023-03-13
Maison d’édition	MDPI
Licence	Creative Commons, Attribution 4.0 International (CC BY 4.0) https://creativecommons.org/licenses/by/4.0/deed.fr
Dans	Viruses 15, nº 3, 739 (13 mars 2023) : 1–2.
Langue	anglais
Publications évaluées par des pairs	Oui
Exporter la notice	Exporter en format RIS
Signaler une correction	Signaler une correction (s'ouvre dans un nouvel onglet)
Identificateur de l’enregistrement	798207c3-8ea9-4d33-9c9e-31aeaa03c84a
Enregistrement créé	2023-08-02
Enregistrement modifié	2023-08-02

Date de modification :: 2024-07-17